AHOD2131: A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Hodgkin Lymphoma
-
Age: Between 5 Year(s) - 60 Year(s)
-
Gender: Male or Female
-
Other Inclusion Criteria:
- Patients who have recently been diagnosed with a specific type of Hodgkin lymphoma called classic Hodgkin lymphoma (cHL) and have not received any treatment for their condition yet
- Patients must have measurable disease which includes at least one lesion with longest diameter greater than or equal to 1.5 cm
- Patients must have a whole body or limited whole body PET scan performed within 42 days prior to enrollment
You may not be eligible for this study if the following are true:
-
- Nodular lymphocyte predominant Hodgkin Lymphoma
- A history of active interstitial pneumonitis or interstitial lung disease
- A diagnosis of inherited or acquired immunodeficiency that is poorly controlled or requiring active medications
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.